Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medicinal composition containing insoluble medicament

A composition and drug technology, applied in the field of pharmaceutical preparations, to achieve the effects of high dispersion, good stability, and strong practicability

Inactive Publication Date: 2011-08-10
张立英
View PDF13 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0021] Therefore, simple oral systemic or local injection administration is not an ideal route and method of administration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing insoluble medicament
  • Medicinal composition containing insoluble medicament
  • Medicinal composition containing insoluble medicament

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] The preparation of embodiment 1 suppository A

[0046] 1. Prescription A (quantity of 100 suppositories)

[0047]

[0048] 2. The preparation method of suppository A

[0049] 1) Take the main ingredients in the prescription and pass through a 200-mesh sieve, and pass through a 100-mesh sieve for other solid materials unless otherwise specified;

[0050] 2) The matrix is ​​melted, filtered, and sterilized at 45-80°C; the main drug in the prescribed amount is miscible with the enhancer (auxiliary, latent) solvent and / or absorption enhancer or is properly heated and melted to form a liquid dispersion;

[0051] 3) Weigh the above-mentioned melted matrix of the prescribed amount, keep warm at 45-55°C, add other excipients of the prescribed amount under stirring and mix evenly, continue to add the above-mentioned liquid dispersion containing the main drug under stirring, and fully mix under the condition of heat preservation. Homogenize to obtain the whole material mixtu...

Embodiment 2

[0054] The preparation of embodiment 2 suppositories B

[0055] 1. Prescription B (amount of 100 suppositories)

[0056]

[0057]

[0058] 2. Preparation method of suppository B

[0059] With embodiment 1.

Embodiment 3

[0060] The preparation of embodiment 3 suppositories C

[0061] 1. Prescription C (amount of 100 suppositories)

[0062]

[0063] 2. The preparation method of suppository C

[0064] With embodiment 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicinal composition containing an insoluble alpha-receptor retardant and / or 5alpha-reductase inhibitor with an effective dose, which comprises the following components of: principal ingredients, a substrate, a solubilizer, a sorbefacient and an additive in a weight ratio of 1:(8-7,000):(0-460):(0-150):(0-150), wherein the medicinal composition at least contains one of the solubilizer and the sorbefacient. The effective dose of the insoluble alpha-receptor retardant and / or the 5alpha-reductase inhibitor is in 0.05 to 80 milligrams of parent compounds of the insoluble alpha-receptor retardant and / or the 5alpha-reductase inhibitor, the weight of a preparation per unit is between 0.8 and 4.2 grams. The medicinal composition can be subjected to oral administration or rectum administration, so the defects of poor curative effect and large toxic and side effect in the conventional oral administration and systemic administration of injection and large side effect and poor compliance of patients in local injection administration can be overcome, the lasting time of the medicinal effect can be increased, and better treatment means can be provided for medical care personnel and patients; and a product process is simple and is suitable for industrial batch production.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, in particular to a (rectal) administration composition containing an α-receptor blocker and / or a 5α-reductase inhibitor, and the preparation of the composition for the treatment of urinary disorders (especially caused by prostate Urination disorder caused by hyperplasia) drug application. Background technique [0002] Diseases that cause voiding disorders are roughly divided into: organic urethral occlusion (including urethral stricture headed by benign prostatic hyperplasia), abnormal innervation of voiding, lower urinary tract syndrome (LUTS, including prostatitis, prostate pain, dysuria , bladder neck sclerosis, bladder neck occlusion, urethral syndrome, detrusor-sphincter dyssynergia, bladder instability, chronic cystitis, Hinman syndrome, Fowler syndrome, psychological voiding disorder, drug-induced voiding disorder, Urination disorders caused by age, including female ur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/517A61K31/4045A61K31/18A61K31/58A61P13/00A61P13/08
Inventor 张立英陈凤仪
Owner 张立英
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products